Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Alnylam Pharmaceuticals's EV/EBITDA was 17.1× on Nov 11, 2026, against 176.8× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.1× | −137.6 |
| 2025 | Dec 31, 2025 | 154.8× | −44.7 |
| 2024 | Oct 31, 2024 | 199.5× | – |
See a number that looks wrong?